Effects of Montelukast sodium combined with Budesonide and Formoterol in treatment of elderly patients with chronic obstructive pulmonary disease
Objective:To observe effects of Montelukast sodium combined with Budesonide and Formoterol in treatment of elderly patients with chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 300 elderly patients with COPD admitted to the hospital from May 2020 to May 2022.According to the random number table method,they were divided into control group and observation group,150 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Budesonide and Formoterol,while the observation group was treated with Montelukast sodium on the basis of that of the control group.Both groups were treated for 14d.The clinical efficacy,the lung function indexes[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC]levels,the blood gas analysis indexes[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2),arterial oxygen saturation(SaO2)]levels,the inflammatory indexes[procalcitonin(PCT),C-reactive protein(CRP),interleukin-6(IL-6)]levels,and the incidence of adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was 98.67%(148/150),which was higher than 90.67%(136/150)of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of FEV1,FVC and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of PaO2 and SaO2 in the observation group were higher than those in the control group,the level of PaCO2 was lower than that in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CRP,IL-6 and PCT in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Budesonide and Formoterol in the treatment of the elderly patients with COPD can improve the total effective rate of treatment,the levels of lung function indexes,improve the levels of blood gas analysis indexes,and reduce the levels of inflammatory indexes.Moreover,it is superior to single Budesonide and Formoterol treatment.
Chronic obstructive pulmonary diseaseBudesonide and FormoterolMontelukast sodiumLung functionBlood gas analysis indexInflammatory indexAdverse reaction
NETL
NSTL
万方数据
维普
